Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Trial of MRTX849 in Combination With Palbociclib in Patients With Advanced Solid Tumors With KRAS G12C Mutation

NCT05178888 is registered in ClinicalTrials.gov with Mirati Therapeutics Inc. as lead sponsor.

NCT NCT05178888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05178888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Trial of MRTX849 in Combination With Palbociclib in Patients With Advanced Solid Tumors With KRAS G12C Mutation
Lead sponsor
Mirati Therapeutics Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 20, 2022
Completion date
December 30, 2024
Enrollment
11 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor